All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

Marek TrněnýExecutive Steering Committee Member

Professor Marek Trněný is a Professor of Medical Oncology and Head of the First Faculty of Medicine at Charles University Hospital, Prague, CZ. He graduated from the Faculty of General Medicine at Charles University, Prague, CZ, in 1985, and until 1989 he worked at the Institute of Chemical Technology, Prague, CZ. Since 1990, Prof. Trněný has worked at the General Teaching Hospital and the First Faculty of Medicine and has completed his residency and fellowship in internal medicine, hematology, and medical oncology. In January 2008, he was appointed Head of the First Internal Clinic of the General Teaching Hospital and First Faculty of Medicine at Charles University, and he was appointed as Professor of Medical Oncology in 2009.

Prof. Trněný’s professional focus is on the pathogenesis and targeted treatment of lymphoma and chronic lymphocytic leukemia, including hematopoietic stem cell transplantation. He has authored and co-authored more than 170 research papers and reviews, and has participated either as principal investigator or sub-investigator in more than 30 clinical trials within the field of hematology.

Positions of responsibility/awards:

  • Founding member of Czech Lymphoma Study Group, and chair since 2004
  • Executive board member of Czech Society of Hematology since 1998
  • Coinvestigator of the European Mantle Cell Lymphoma Network
  • Member of Lymphoma Scientific Working Group of the European Hematology Association (EHA)
  • Member of the European Society for Medical Oncology (ESMO) Educational Committee for hematologic tumors
  • Member of the American Society of Hematology (ASH)
  • Head of Lymphoma group and Stem Cell Transplantation program at the General Hospital, Charles University, Prague, CZ